Identification of differential expression phenotypes of CD133+ stem cells in acute and chronic myocardial infarct patients and specific expression pathways underpinning therapeutic responsiveness in regenerative therapy

      Background: Therapeutic benefits of cell therapy remain modest due to varying cell phenotypes from different patients and the poor survival of transplanted cells. IMPACT-CABG and COMPARE-AMI trials represent the first North American phase II randomized studies of autologous CD133+ stem cells delivered in the heart post myocardial infarction (MI). Cells were delivered in patients suffering from chronic ischemic cardiomyopathy through transepicardial injections during CABG procedure (IMPACT-CABG) and by intracoronary route during PCI and stenting <7 days following MI (COMPARE-AMI). With banked stem cells, we set out to identify the CD133+ expression phenotypes in both patient populations and identify transcriptomic signatures responsible for therapeutic effectiveness.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect